The short-term effects of recombinant human growth hormone on children with growth hormone deficiency and idiopathic short stature: a retrospective study
Keywords:
Curative effect, Short stature, Growth hormone deficiency, Idiopathic short stature, Recombinant Human Growth HormoneAbstract
Background: To evaluate the short-term efficacy and safety of recombinant human growth hormone (rhGH) in treating children with growth hormone deficiency (GHD) or idiopathic short stature (ISS). Methods: Records of children diagnosed with GHD or ISS at Yulin Maternal and Child Health Care Hospital of Guangxi from April 2021 to February 2023 were analyzed. Of 90 children, 33 had GHD and 57 had ISS. Results: Post-rhGH treatment, significant elevation in height, weight, bone age and IGF-1 level was observed in both groups at 6 and 12 months. The efficacy was similar for both conditions, except for a distinction in bone age at 6 months. No difference was seen in the effectiveness of rhGH in powder vs. liquid form. Insulin levels increased post-treatment, with no change in liver, kidney, and thyroid parameters for GHD children. However, significant changes were seen in ISS children's liver, kidney, and thyroid parameters. Adverse reaction rates were comparable between groups. Conclusions: rhGH improved the growth velocity/year in GHD or ISS children. Notably, some changes in the liver, kidney, and thyroid parameters were observed in children with ISS after rhGH treatment. It indicates the importance of monitoring these functional indicators, although the exact magnitude and clinical significance of these changes need further investigation.
References
Tritos NA, Biller BMK. Current concepts of the diagnosis of adult growth hormone deficiency. Rev Endocr Metab Disord. 2021; 22(1):109-16. doi: 10.1007/s11154-020-09594-1.
Yuan J, Du Z, Wu Z,et al. A Novel Diagnostic Predictive Model for Idiopathic Short Stature in Children. Front Endocrinol (Lausanne). 2021;12:721812. doi: 10.3389/fendo.2021.721812.
Richmond E, Rogol AD. Treatment of growth hormone deficiency in children, adolescents and at the transitional age. Best Pract Res Clin Endocrinol Metab. 2016; 30(6):749-55. doi: 10.1016/j.beem.2016.11.005.
Guichelaar MM, Malinchoc M, Sibonga JD, Clarke BL, Hay JE. Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease. J Bone Miner Res. 2003; 18(12):2190-2199. doi: 10.1359/jbmr.2003.18.12.2190.
Drube J, Wan M, Bonthuis M, et al. Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat Rev Nephrol. 2019; 15(9):577-89. doi: 10.1038/s41581-019-0161-4. P
Witkowska-Sędek E, Borowiec A, Majcher A, Sobol M, Rumińska M, Pyrżak B. Thyroid function in children with growth hormone deficiency during long-term growth hormone replacement therapy. Cent Eur J Immunol. 2018; 43(3):255-61. doi: 10.5114/ceji. 2018.80043.
Hill DJ, Milner RD. Insulin as a growth factor. Pediatr Res. 1985; 19(9):879-86. doi: 10.1203/00006450-198509000-00001.
Mohammad NS, Nazli R, Zafar H, Fatima S. Effects of lipid based Multiple Micronutrients Supplement on the birth outcome of underweight pre-eclamptic women: A randomized clinical trial. Pak J Med Sci. 2022; 38(1):219-26. doi:10.12669/pjms.38.1.4396.
Wen H, Jung H, Li X. Drug Delivery Approaches in Addressing Clinical Pharmacology-Related Issues: Opportunities and Challenges. Aaps j. 2015; 17(6):1327-40. doi: 10.1208/s12248-015-9814-9.
Fuhr U, Tuculanu D, Berghout A, Balser S, Schwebig A, Saenger P. Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin. Eur J Endocrinol. 2010; 162(6):1051-8. doi: 10.1530/eje-09-1101.
Ayyar VS. History of growth hormone therapy. Indian J Endocrinol Metab. 2011; 15 Suppl 3(Suppl3):S162-5. doi: 10.4103/2230-8210.84852.
Gupta V, Lee M. Growth hormone in chronic renal disease. Indian J Endocrinol Metab. 2012; 16(2):195-203. doi: 10.4103/2230-8210.93736.
Quitmann JH, Bullinger M, Sommer R, Rohenkohl AC, Bernardino Da Silva NM. Associations between Psychological Problems and Quality of Life in Pediatric Short Stature from Patients' and Parents' Perspectives. PLoS One. 2016; 11(4):e0153953. doi: 10.1371/journal.pone.0153953.
Quigley CA, Child CJ, Zimmermann AG, Rosenfeld RG, Robison LL, Blum WF. Mortality in Children Receiving Growth Hormone Treatment of Growth Disorders: Data From the Genetics and Neuroendocrinology of Short Stature International Study. J Clin Endocrinol Metab. 2017; 102(9):3195-3205. doi: 10.1210/jc.2017-00214.
Ranke MB, Lindberg A, Chatelain P, ,et al. Prediction of long-term response to recombinant human growth hormone in Turner syndrome: development and validation of mathematical models. KIGS International Board. Kabi International Growth Study. J Clin Endocrinol Metab. 2000; 85(11):4212-8. doi: 10.1210/jcem.85.11.6976.
van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, et al. Final height in girls with turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. J Clin Endocrinol Metab. 2003; 88(3):1119-25. doi: 10.1210/jc.2002-021171.
Romer T, Peter F, Saenger P, et al. Efficacy and safety of a new ready-to-use recombinant human growth hormone solution. J Endocrinol Invest. 2007; 30(7):578-89. doi: 10.1007/bf03346352.
Wu B, Lin H, Gao J, Sun J, Zhao M. Effects of high-dose recombinant human growth hormone treatment on IGF-1 and IGFBP-3 levels in idiopathic dwarfism patients. Pak J Med Sci. 2022; 38(4Part-II):1038-42. doi: 10.12669/pjms.38.4.5502. PMID: 35634620.
Gou P, Cheng X, Leng J, Su N. A Real-World Study of Recombinant Human Growth Hormone in the Treatment of Idiopathic Short Stature and Growth Hormone Deficiency. Ther Clin Risk Manag. 2022; 18:113-24. doi: 10.2147/tcrm.S363564.
Kang MJ, Kim EY, Shim YS, Jeong HR, Lee HJ, Yang S, Hwang IT. Factors affecting bone age maturation during 3 years of growth hormone treatment in patients with idiopathic growth hormone deficiency and idiopathic short stature: Analysis of data from the LG growth study. Medicine (Baltimore). 2019; 98(14):e14962. doi: 10.1097/md.0000000000014962.
Cheng YH, Dyer AM, Jabbal-Gill I, Hinchcliffe M, Nankervis R, Smith A, Watts P. Intranasal delivery of recombinant human growth hormone (somatropin) in sheep using chitosan-based powder formulations. Eur J Pharm Sci. 2005; 26(1):9-15. doi: 10.1016/j.ejps.2005.03.014.
Cai Y, Xu M, Yuan M, Liu Z, Yuan W. Developments in human growth hormone preparations: sustained-release, prolonged half-life, novel injection devices, and alternative delivery routes. Int J Nanomedicine. 2014; 9:3527-38. doi: 10.2147/ijn.S63507.
Gurevich E, Segev Y, Landau D. Growth Hormone and IGF1 Actions in Kidney Development and Function. Cells. 2021; 10(12). doi: 10.3390/cells10123371.
Witkowska-Sędek E, Kucharska AM, Rumińska M, Paluchowska M, Pyrżak B. Decreased Thyroxine Levels during rhGH Therapy in Children with Growth Hormone Deficiency. J Clin Med. 2021; 10(21). doi: 10.3390/jcm10215100.
Xue J, Liang S, Ma J, Xiao Y. Effect of growth hormone therapy on liver enzyme and other cardiometabolic risk factors in boys with obesity and nonalcoholic fatty liver disease. BMC Endocr Disord. 2022; 22(1):49. doi: 10.1186/s12902-022-00967-y.
Ji B, Zhang M, Zhao Q, et al. Association between Alanine Aminotransferase and Growth Hormone: A Retrospective Cohort Study of Short Children and Adolescents. Biomed Res Int. 2019; 2019:5939372. doi: 10.1155/2019/5939372.
Witkowska-Sędek E, Stelmaszczyk-Emmel A, Majcher A, Demkow U, Pyrżak B. The relationship between alkaline phosphatase and bone alkaline phosphatase activity and the growth hormone/insulin-like growth factor-1 axis and vitamin D status in children with growth hormone deficiency. Acta Biochim Pol. 2018; 65(2):269-75. doi: 10.18388/abp.2017_2541.
Davani-Davari D, Karimzadeh I, Khalili H. The potential effects of anabolic-androgenic steroids and growth hormone as commonly used sport supplements on the kidney: a systematic review. BMC Nephrol. 2019; 20(1):198. doi: 10.1186/s12882-019-1384-0.
Kucharska AM, Witkowska-Sędek E, Rumińska M, Pyrżak B. Thyroid Hormone Changes Related to Growth Hormone Therapy in Growth Hormone Deficient Patients. J Clin Med. 2021; 10(22). doi: 10.3390/jcm10225354.
Hou L, Liang Y, Wu W, Lin HH, Luo XP, Ying YQ. Comparison of the efficacy and safety of recombinant human growth hormone in treating idiopathic short stature and growth hormone deficiency in children. Growth Horm IGF Res. 2020; 53-4:101331. doi: 10.1016/j.ghir.2020.101331.
Rui L, Fisher TL, Thomas J, White MF. Regulation of insulin/insulin-like growth factor-1 signaling by proteasome-mediated degradation of insulin receptor substrate-2. J Biol Chem. 2001; 276(43):40362-7. doi: 10.1074/jbc.M105332200.
Maghnie M, Ranke MB, Geffner ME, et al. Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort. J Clin Endocrinol Metab. 2022; 107(12):3287-301. doi: 10.1210/clinem/dgac517.
Miller BS, Velazquez E, Yuen KCJ. Long-Acting Growth Hormone Preparations - Current Status and Future Considerations. J Clin Endocrinol Metab. 2020; 105(6):e2121-33. doi: 10.1210/clinem/dgz149.
Al Shaikh A, Daftardar H, Alghamdi AA, et al. Effect of growth hormone treatment on children with idiopathic short stature (ISS), idiopathic growth hormone deficiency (IGHD), small for gestational age (SGA) and Turner syndrome (TS) in a tertiary care center. Acta Biomed. 2020; 91(1):29-40. doi: 10.23750/abm.v91i1.9182.
Lecka-Ambroziak A, Wysocka-Mincewicz M, Dolezal-Oltarzewska K, et al. Effects of Recombinant Human Growth Hormone Treatment, Depending on the Therapy Start in Different Nutritional Phases in Paediatric Patients with Prader-Willi Syndrome: A Polish Multicentre Study. J Clin Med. 2021; 10(14). doi: 10.3390/jcm10143176..
Allen DB. Safety of growth hormone treatment of children with idiopathic short stature: the US experience. Horm Res Paediatr. 2011; 76 (Suppl 3):45-7. doi: 10.1159/000330159.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Mei Li, Jun Feng, Liqin Chen, Dongmei Huang, Xia Wu, Zhang ZHANG, Wenmin Wang
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
How to Cite
